PMID- 9175329
OWN - NLM
STAT- MEDLINE
DCOM- 19970624
LR  - 20131121
IS  - 0390-6078 (Print)
IS  - 0390-6078 (Linking)
VI  - 82
IP  - 2
DP  - 1997 Mar-Apr
TI  - Hyperhomocysteinemia and venous thromboembolic disease.
PG  - 211-9
AB  - BACKGROUND AND OBJECTIVE: In spite of the large number of reports showing that 
      hyperhomocysteinemia (HHcy) is an independent risk factor for atherosclerosis and 
      arterial occlusive disease, this metabolite of the methionine pathway is measured 
      in relatively few laboratories and its importance is not fully appreciated. 
      Recent data strongly suggest that mild HHcy is also involved in the pathogenesis 
      of venous thromboembolic disease. The aim of this paper is to analyze the most 
      recent advances in this field. EVIDENCE AND INFORMATION SOURCES: The material 
      examined in the present review includes articles and abstracts published in 
      journals covered by the Science Citation Index and Medline. In addition the 
      authors of the present article have been working in the field of mild HHcy as 
      cause of venous thromboembolic disease. STATE OF ART AND PERSPECTIVES: The 
      studies examined provide very strong evidence supporting the role of moderate 
      HHcy in the development of premature and/or recurrent venous thromboembolic 
      disease. High plasma homocysteine levels are also a risk factor for deep vein 
      thrombosis in the general population. Folic acid fortification of food has been 
      proposed as a major tool for reducing coronary artery disease mortality in the 
      United States. Vitamin supplementation may also reduce recurrence of venous 
      thromboembolic disease in patients with HHcy. At the present time, however, the 
      clinical efficacy of this approach has not been tested. In addition, the bulk of 
      evidence indicates that fasting total homocysteine determinations can identify up 
      to 50% of the total population of hyperhomocysteinemic subjects. Patients with 
      isolated methionine intolerance may benefit from vitamin B6 supplementation. 
      Homocysteine-lowering vascular disease prevention trials are urgently needed. 
      Such controlled studies, however, should not focus exclusively on fasting 
      homocysteine determinations and folic acid monotherapy.
FAU - D'Angelo, A
AU  - D'Angelo A
AD  - Coagulation Service, Scientific Institute H San Raffaele, Milan, Italy.
FAU - Mazzola, G
AU  - Mazzola G
FAU - Crippa, L
AU  - Crippa L
FAU - Fermo, I
AU  - Fermo I
FAU - Vigano D'Angelo, S
AU  - Vigano D'Angelo S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Italy
TA  - Haematologica
JT  - Haematologica
JID - 0417435
RN  - 0LVT1QZ0BA (Homocysteine)
SB  - IM
MH  - Homocysteine/*blood
MH  - Humans
MH  - Risk Factors
MH  - Thrombophlebitis/*etiology
RF  - 127
EDAT- 1997/03/01 00:00
MHDA- 1997/03/01 00:01
CRDT- 1997/03/01 00:00
PHST- 1997/03/01 00:00 [pubmed]
PHST- 1997/03/01 00:01 [medline]
PHST- 1997/03/01 00:00 [entrez]
PST - ppublish
SO  - Haematologica. 1997 Mar-Apr;82(2):211-9.